BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioXcel Therapeutics (BTAI) PT Raised to $128 at Truist Securities
May 10, 2021 12:13 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining a Buy rating.
The analyst commented, "Key 1Q21 takeaways: 1) commercial US prep on track for '501 key indications launching 1Q22; 2) '501 EU market may provide... More
BioXcel Therapeutics (BTAI) Reports Q1 Loss of $1.08/sh
May 10, 2021 7:17 AM EDTBioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.08), versus ($0.79) reported last year.
For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.
... More